ClinicalTrials.gg
CompletedNCT02115113REFLECTUpdated Feb 28, 2019Results posted

REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy

A Phase 3 interventional study of Everolimus and Tacrolimus in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C virus (HCV), hepatocellular carcinoma (HCC), and short/long-term implications. Then efficacy and safety of a calcineurin inhibitor (CNI)-withdrawal regimen was evaluated in comparison with a CNI-minimization regimen.

02

Conditions studied

  • Liver Transplantation

Keywords

  • Liver transplantation, everolimus, CNI-minimization, CNI-elimination, renal function
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria at Baseline:

  • Male and female liver transplant recipients who are ≥ 18 years of age, treated with a tacrolimus-based regimen, who have received an induction therapy or i.v. as per local clinical practice.
  • Recipients of a full-size or technically modified liver allograft will be eligible at 4 weeks (± 7 days) after liver transplantation.
  • Allograft is functioning at an acceptable level by the time of Baseline as defined by the , ALT, total levels ≤ 3 times and \< 1.5 times ULN.
  • Abbreviated -4 eGFR ≥ 30 mL/min/1.73m2. Serum creatinine results obtained within 5 days prior to Baseline are acceptable.

Inclusion criteria at Randomization:

  • Effective tacrolimus minimization, confirmed by stable blood trough levels in the two months prior to randomization, i.e. verification of last two tacrolimus blood trough level ≤ 5 ng/mL in the two months prior to randomization. Investigators should make adjustments in tacrolimus dosing to continue to target trough levels ≤ 5 ng/mL prior to randomization.
  • Abbreviated MDRD-4 eGFR ≥ 30 mL/min/1.73m2. Serum creatinine results obtained within 5 days prior to Visit 5 are acceptable.

Exclusion criteria at Baseline:

  • Patients who are recipients of multiple solid organ transplants, (e.g., multivisceral or combined liver-kidney transplants), or have previously received an organ or tissue transplanted, or who received an AB0 incompatible transplant.
  • Patients who experienced more than one episode of treated proven acute rejection (BANFF ≥ 3 or RAI ≥ 7) or one steroid-resistant acute rejection.
  • Patients who require renal replacement therapy.
  • Patients with a confirmed spot urine protein/creatinine ratio that indicates ≥1.0 g/24 hrs of proteinuria.
  • History of of any organ system within the past 5 years whether or not there is evidence of local recurrence or , other than non-metastatic basal or squamous cell carcinoma of the skin or HCC.

Exclusion criteria at Randomization:

  • Patients who experienced more than two episodes of treated biopsy proven acute rejection (BANFF ≥ 3 or RAI ≥ 7) since transplantation or one steroid-resistant acute rejection during the run-in period.
  • Patients with a confirmed spot urine protein/creatinine ratio that indicates ≥ 3.0 g/24 hrs of proteinuria.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Group A (Tacrolimus Elimination Arm)

    At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.

    Drug: Everolimus · Drug: Tacrolimus

  • Active comparator
    Group B (Tacrolimus Minimization Arm)

    At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.

    Drug: Everolimus · Drug: Tacrolimus

Interventions

  • Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.

  • Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.

06

What researchers measure

Primary outcomes

  1. Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR)

    Renal function was assessed by eGFR using the MDRD-4 formula at 12 months after transplant: eGFR = 186.3 \* (serum creatinine)-1.154 \* age-0.203 \* (0.742 for women) \* (1.21 if African American) where serum creatinine was in mg/dL and age in years.

    Time frame: At 12 months post-transplant

Secondary outcomes

  1. Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D)

    Participants were assessed for tBPAR, AR, GL or death. For all suspected rejection episodes, regardless of initiation of anti-rejection treatment, a liver biopsy was to be performed preferably within 24 hours, latest within 48 hours whenever clinically possible. A treated biopsy proven acute rejection was considered an episode of acute rejection when demonstrated by local pathology reading with a rejection activity index of at least 3 or greater of acute rejection index and when treated with anti-rejection therapy. The allograft was considered lost on the day the subject was re-transplanted or died due to liver failure.

    Time frame: At 12 and 18 months post-transplant

  2. Change From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant

    Blood samples were collected to assess serum creatinine.

    Time frame: baseline, 12 months post-transplant

07

Results

Posted Feb 28, 2019

Participant flow

68 participants completed run-in but only 50 decided to move forward to randomization.

Participants in Run-in Period
Participant flow — Participants in Run-in Period
MilestoneGroup A (Tacrolimus Elimination Arm)Group B (Tacrolimus Minimization Arm)Total Enrolled at run-in
Started0078
Completed0068
Not completed0010
Withdrew: Death001
Withdrew: Administrative problems001
Withdrew: Lost to follow-up005
Withdrew: Withdrawal by subject003
Participants Randomized
Participant flow — Participants Randomized
MilestoneGroup A (Tacrolimus Elimination Arm)Group B (Tacrolimus Minimization Arm)Total Enrolled at run-in
Started24260
Completed22260
Not completed200
Withdrew: Lost to follow-up100
Withdrew: Death100

Outcome measures

PrimaryRenal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR)

Renal function was assessed by eGFR using the MDRD-4 formula at 12 months after transplant: eGFR = 186.3 \* (serum creatinine)-1.154 \* age-0.203 \* (0.742 for women) \* (1.21 if African American) where serum creatinine was in mg/dL and age in years.

Time frame:
At 12 months post-transplant
Reported as:
Least squares mean · mL/min/1.73m^2
Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR)
mL/min/1.73m^2Group A (Tacrolimus Elimination Arm)Group B (Tacrolimus Minimization Arm)
Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR)85.50 ± 3.9780.26 ± 3.87
Statistical analysis
  • Group A (Tacrolimus Elimination Arm) vs Group B (Tacrolimus Minimization Arm) · ANOVA · p = 0.3013 · Mean difference (net): 5.24 · 95% CI -4.86 to 15.34
SecondaryPercentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D)

Participants were assessed for tBPAR, AR, GL or death. For all suspected rejection episodes, regardless of initiation of anti-rejection treatment, a liver biopsy was to be performed preferably within 24 hours, latest within 48 hours whenever clinically possible. A treated biopsy proven acute rejection was considered an episode of acute rejection when demonstrated by local pathology reading with a rejection activity index of at least 3 or greater of acute rejection index and when treated with anti-rejection therapy. The allograft was considered lost on the day the subject was re-transplanted or died due to liver failure.

Time frame:
At 12 and 18 months post-transplant
Reported as:
Count of participants · Participants
Percentage of Participants With Treated Biopsy Proven Acute Rejection (tBPAR) Acute Rejection (AR), Graft Loss (GL) or Death (D)
ParticipantsGroup A (Tacrolimus Elimination Arm)Group B (Tacrolimus Minimization Arm)
tBPAR, 12 months21
AR, 12 months21
GL, 12 months00
Death, 12 months10
tBPAR, 18 months21
AR, 18 months21
GL, 18 months00
Death, 18 months11
SecondaryChange From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant

Blood samples were collected to assess serum creatinine.

Time frame:
baseline, 12 months post-transplant
Reported as:
Least squares mean · mg/dL
Change From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant
mg/dLGroup A (Tacrolimus Elimination Arm)Group B (Tacrolimus Minimization Arm)
Change From Baseline (Randomization) in Serum Creatinine at 12 Months Post-transplant-0.11 ± 0.04-0.05 ± 0.03

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Population Total—25/78 (32.1%)57/78 (73.1%)
Run-in Population Tacrolimus Elimination—4/24 (16.7%)20/24 (83.3%)
Run-in Population Tacrolimus Minimization—9/26 (34.6%)21/26 (80.8%)
Randomization Treatment Period Tacrolimus Elimination—4/24 (16.7%)16/24 (66.7%)
Randomization Treatment Period Tacrolimus Minimization—9/26 (34.6%)15/26 (57.7%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventRun-in Population TotalRun-in Population Tacrolimus EliminationRun-in Population Tacrolimus MinimizationRandomization Treatment Period Tacrolimus EliminationRandomization Treatment Period Tacrolimus Minimization
Aspartate aminotransferase increasedInvestigations7/782/241/260/240/26
CholangitisHepatobiliary disorders3/782/240/260/240/26
LeukopeniaBlood and lymphatic system disorders0/780/240/260/242/26
PyrexiaGeneral disorders5/780/242/261/241/26
Blood bilirubin increasedInvestigations6/781/242/260/240/26
Alanine aminotransferase increasedInvestigations5/781/241/261/240/26
PericarditisCardiac disorders0/780/240/261/240/26
AscitesGastrointestinal disorders1/781/240/260/240/26
Bile duct stenosisHepatobiliary disorders0/780/240/261/240/26
Liver disorderHepatobiliary disorders1/781/240/260/240/26
Most frequent other events
Showing 10 of 36
Most frequent other events
EventRun-in Population TotalRun-in Population Tacrolimus EliminationRun-in Population Tacrolimus MinimizationRandomization Treatment Period Tacrolimus EliminationRandomization Treatment Period Tacrolimus Minimization
Oedema peripheralGeneral disorders3/780/241/265/241/26
AnaemiaBlood and lymphatic system disorders5/780/243/260/245/26
PyrexiaGeneral disorders14/784/244/263/244/26
AstheniaGeneral disorders7/784/241/260/240/26
Blood alkaline phosphatase increasedInvestigations3/780/241/264/240/26
Gamma-glutamyltransferase increasedInvestigations4/781/242/264/242/26
Transaminases increasedInvestigations9/784/244/262/242/26
LeukopeniaBlood and lymphatic system disorders6/780/244/261/242/26
Diabetes mellitusMetabolism and nutrition disorders6/781/244/261/241/26
NauseaGastrointestinal disorders8/783/242/260/241/26

Baseline characteristics

Run-in Population: all consented and everolimus-treated patients who entered the run-in treatment period. All 78 enrolled patients were included in the run-in treatment period. Treatment started at the randomization period.

Age, Continuous
Age, Continuous(Years)Total Enrolled at run-in
Mean53.73 ± 9.69
Sex: Female, Male
Sex: Female, Male(Participants)Total Enrolled at run-in
Female19
Male59
08

Study locations

14 sites
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Pisa, PI 56124, Italy
  • Novartis Investigative Site
    Roma, RM 00144, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Verona, VR 37126, Italy
  • Novartis Investigative Site
    Napoli, 80132, Italy
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Sep 2016, 30 months.

Results were first posted in Feb 2019, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2014
First posted
Apr 15, 2014
StartActual
Mar 28, 2014
Primary completionActual
Sep 30, 2016
CompletionActual
Sep 30, 2016
Results first posted
Feb 28, 2019
Last update
Feb 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02115113
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Mar 28, 2014
Primary completion
Sep 30, 2016
Completion
Sep 30, 2016
Results posted
Feb 28, 2019
Last update
Feb 28, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Tacrolimus

Start the discussion